Arthneeti
B

Biocon

Q1 FY27Pharmaceuticals & Biotechnology

Biocon Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹415
Market cap₹67.7K Cr
P/E93.1
Updated25 Aug 2026
Read5 min read

What the Q1 FY27 call signalled

0 of 3 strong

RevenueRank 3
MarginRank 3
CapexNo

Not discussed on this call: fundraise, order book.

The short version

Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10). Biosimilars business expected to show meaningful acceleration in growth, especially in the second half of FY27, driven by recent launches and expanded manufacturing capacity.

From Biocon's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Rank 3
  • Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10).
  • Generics business showing healthy revenue growth (21% YoY) with new launches like liraglutide contributing; further scale-up expected (Page 7, 10).
  • Continued new product launches planned annually in biosimilars through the end of the decade to sustain growth (Page 17).
  • Insulin franchise expansion supported by manufacturing capacity increase with EMA approval, expected to drive global demand (Page 6).
  • Aflibercept launched in US ophthalmology market with strong growth opportunities anticipated (Page 9, 15).
  • Focus on calibrated profitable growth rather than just market share to ensure sustainable revenue and margin expansion (Page 9, 18).
  • Syngene expected to improve performance in second half of FY27 after first-half challenges, with return to profitable growth from FY28 (Page 7).
  • Overall, steady growth with increasing volumes and revenues expected, particularly in second half of FY27.

Profitability & Margins

See what Biocon said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

No
  • Biocon currently holds a small stake in Bicara but is not contemplating monetizing it immediately; monetization will be considered at the right time given Bicara's strong performance (Page 21).
  • Regarding manufacturing in the USA, Biocon does not plan to increase capital expenditure to establish new facilities or capacities; instead, they focus on partnerships and utilizing existing manufacturing facilities (Page 20).
  • The Biocon Group is looking at having a local manufacturing footprint where needed, primarily through partnerships rather than building new plants (Page 20).
  • There is ongoing investment in working capital, particularly inventory, to support expected scale-up in biosimilars and generics in the second half of the year (Page 19).
  • Cost optimization and strategic R&D investments are ongoing, with a focus on strategic, high-growth opportunities rather than opportunistic spending (Pages 18, 10).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1Accretion Pha.
Rev 1Mar 2
2OneSource Specialty Pharma Ltd
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Biocon said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript does not provide explicit details on the current or expected order book or pending orders for Biocon Limited. However, the following relevant points can be inferred: - Biosimilars business is the core growth engine with strong traction and expanded manufacturing capability. - Momentum is expected to build progressively through FY27 with meaningful acceleration in the second half. - New product launches, including biosimilars and generics, are scaling up to contribute to revenue growth. - The company is prepared for increased demand, supported by manufacturing milestones such as EMA approval of new insulin production lines. - Focus remains on profitable growth, balancing new launches with operational efficiencies. - Working capital and inventory increases are aligned with preparation for scale-up in the second half. - Partnerships and manufacturing footprint expansion are being considered strategically but no increase in US capex for new facilities at present. No specific order backlog or pending order volumes or values are disclosed.

Biocon — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹4.5K Cr, net profit ₹199 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Biocon Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Novartis India Ltd (Q1 FY27)

    Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…

  • IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharmaceuticals Ltd (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divis Laboratories Ltdvs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Biocon Q1 FY27 results?

Biosimilars business expected to see meaningful acceleration in second half of FY27 with new product launches driving growth (Page 6, 9, 10). Biosimilars business expected to show meaningful acceleration in growth, especially in the second half of FY27, driven by recent launches and expanded manufacturing capacity.

What is Biocon share price analysis?

Biocon currently shows a below-average growth signal. The stock trades at a P/E of 93.1 with a market cap of ₹67,722 Cr. Investors should review the full earnings analysis for detailed insights.

Is Biocon planning capital expenditure?

Biocon currently holds a small stake in Bicara but is not contemplating monetizing it immediately; monetization will be considered at the right time given Bicara's strong performance (Page 21).

Keep Biocon on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.